![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AKANTIOR® (polihexanide) stands to become first approved drug for the treatment of acanthamoeba keratitis in the world. It is an anti-amoebic polymer that acts on both the trophozoites and cysts of the protozoan Acanthamoeba.
Lead Product(s): Polyhexanide
Therapeutic Area: Infections and Infectious Diseases Product Name: Akantior
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: SIFI
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022